Endocrinology, Vol 117, 2008-2016, Copyright © 1985 by Endocrine Society

ARTICLES

Insulin and insulin-like growth factor (somatomedin) receptors on cloned rat pituitary tumor cells

RG Rosenfeld, G Ceda, CW Cutler, LA Dollar and AR Hoffman

Specific receptors for insulin and the somatomedin peptides insulin- like growth factors I and II (IGF-I and IGF-II) have been characterized on three separate cloned strains of rat pituitary tumor cells (GH3, GH1, and GC). Binding of 125I-labeled peptides was time, temperature, and pH dependent for all three cell lines. Specific binding of [125I]insulin, which was extremely low in normal rat adenohypophyseal cells, was demonstrable for all three lines, with the Kd for the high affinity receptor ranging from 10(-10) to 4 X 10(-10) M/liter. A specific high affinity IGF-I receptor was also identified, with a Kd of approximately 10(-9) M/liter. IGF-II and insulin were, respectively, 10% and 1% as potent as IGF-I in competing for this receptor. When [125I]insulin and [125I]IGF-I were cross-linked to GH3 cells with disuccinimidyl suberate, followed by sodium dodecyl sulfate- polyacrylamide gel electrophoresis, both receptors were found to have an apparent mol wt greater than 300,000 in the unreduced state, with subunits of apparent mol wt 125,000 after reduction. A third discrete receptor, which bound [125I]IGF-II, was also identified on all three cell lines. IGF-I was only 10% as potent as IGF-II at displacing [125I]IGF-II, and insulin was virtually unreactive. When [125I]IGF-II was cross-linked to GH3 cells and analyzed by sodium dodecyl sulfate- polyacrylamide gel electrophoresis, two receptors were identified. One had an apparent mol wt of 205,000 unreduced and 250,000 upon reduction, and presumably represents the type II receptor. Additionally, a band was observed at an apparent mol wt greater than 300,000 unreduced and 125,000 upon reduction, probably representing IGF-II binding to the IGF- I or insulin receptor. The presence of specific high affinity receptors for insulin, IGF-I, and IGF-II in these transformed cell lines is consistent with previous observations in normal rat and human pituitary cells and suggests a role for these peptides in the modulation of pituitary function.

This article has been cited by other articles:

				M Fernandez, F Sanchez-Franco, N Palacios, I Sanchez, and L Cacicedo IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1 J. Mol. Endocrinol., June 1, 2005; 34(3): 699 - 712. [Abstract] [Full Text] [PDF]

				S. Fruchtman, D. C. McVey, and R. J. Borski Characterization of pituitary IGF-I receptors: modulation of prolactin and growth hormone Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R468 - R476. [Abstract] [Full Text] [PDF]

				A. Niiori-Onishi, Y. Iwasaki, N. Mutsuga, Y. Oiso, K. Inoue, and H. Saito Molecular Mechanisms of the Negative Effect of Insulin-Like Growth Factor-I on Growth Hormone Gene Expression in MtT/S Somatotroph Cells Endocrinology, January 1, 1999; 140(1): 344 - 349. [Abstract] [Full Text]

				A. I. Castillo and A. Aranda Differential Regulation of Pituitary-Specific Gene Expression by Insulin-Like Growth Factor 1 in Rat Pituitary GH4C1 and GH3 Cells Endocrinology, December 1, 1997; 138(12): 5442 - 5451. [Abstract] [Full Text] [PDF]

				R. Lanzi, M. F. Manzoni, A. C. Andreotti, M. E. Malighetti, E. Bianchi, L. P. Sereni, A. Caumo, L. Luzi, and A. E. Pontiroli Evidence for an Inhibitory Effect of Physiological Levels of Insulin on the Growth Hormone (GH) Response to GH-Releasing Hormone in Healthy Subjects J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2239 - 2243. [Abstract] [Full Text] [PDF]

				D. Ray and S. Melmed Pituitary Cytokine and Growth Factor Expression and Action Endocr. Rev., April 1, 1997; 18(2): 206 - 228. [Abstract] [Full Text]